AGRYLIN

LOE Approaching

anagrelide hydrochloride

NDAORALCAPSULEPriority Review
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Clinical Trials (5)

NCT03866434Phase 1Completed

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

Started Feb 2019
20 enrolled
Healthy Volunteers
NCT03625895N/ACompleted

Agrylin Drug Use-Result Survey

Started Nov 2014
1,826 enrolled
Essential Thrombocythemia (ET)
NCT01552928Phase 1Completed

Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers

Started Mar 2012
60 enrolled
Healthy
NCT01467661Phase 3Completed

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Started Oct 2010
41 enrolled
Essential Thrombocythemia (ET)
NCT01214915Phase 3Completed

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

Started Oct 2010
53 enrolled
Essential Thrombocythemia (ET)